Biologic disc repair — specifically, intra-annular fibrin injection targeting a confirmed annular tear — produced an 80% reduction in VAS pain scores and avoided revision fusion in this illustrative failed back surgery syndrome case. The patient progressed from severe functional limitation to restored daily activity over 24 months. Individual outcomes vary.

Editorial note: The following is a composite illustrative scenario drawn from clinical patterns seen in failed back surgery syndrome patients. It is not a specific patient’s record. No identifying information represents a real individual. This case is presented for educational purposes only.

Case Snapshot

• Illustrative patient profile: 54-year-old retired commercial construction worker
• Diagnosis pattern: Failed back surgery syndrome (FBSS) with adjacent-level annular tears at L4-L5; prior L5-S1 fusion six years earlier
• Constraints: Refused revision fusion; prior epidural steroid injections provided no durable relief; opioid avoidance was a personal priority
• Approach: Intra-annular fibrin injection targeting the symptomatic annular defect at L4-L5, paired with structured rehabilitation
• Outcomes: VAS pain score moved from 72 mm at baseline to 33 mm at 104 weeks; functional restoration of walking tolerance, sleep, and daily activities; revision fusion avoided. Individual outcomes vary.

This case fits within the broader clinical landscape of failed back surgery syndrome and adjacent segment disease — two conditions that drive a significant share of revision spine consultations. For context on how adjacent segment disease develops after fusion, that resource walks through the mechanism in plain English.

What Is the Clinical Context for This Case?

Failed back surgery syndrome describes the continuation or recurrence of chronic pain after technically successful spinal surgery. It is more common than many patients expect: back surgery carries roughly a 40% failure rate by some industry consensus estimates, and adjacent segment disease — where a fused spinal level places increased mechanical stress on neighboring discs — is a recognized driver of recurrent symptoms.

In this illustrative scenario, a retired construction superintendent spent more than three decades on heavy job sites before undergoing a single-level posterior lumbar interbody fusion at L5-S1 for severe discogenic pain. The surgery resolved radicular pain for approximately 18 months. After that window, low back pain returned — this time centered slightly higher in the lumbar spine. By the time this type of patient reaches evaluation, that ache has typically escalated into constant axial pain with intermittent lower-extremity radiation.

Baseline measurements in this pattern typically document significant severity. VAS pain of 72 mm out of 100 is consistent with published cohort data showing a mean baseline of 72.4 mm in fibrin outcome studies. Functional limitations in this profile include reduced walking tolerance, disrupted sleep, and withdrawal from activities that define quality of life — fishing, woodworking, lifting grandchildren.

MRI findings in this pattern: a solid prior fusion construct, mild facet arthropathy throughout the lumbar spine, and a posterior annular tear at the adjacent level with high-intensity zone signal and a small contained protrusion. Provocative discography, performed only after extensive conservative care had failed, reproduced concordant axial pain at the adjacent level and was negative at levels above.

How Does Clinical Assessment Shape the Treatment Decision?

Framing the problem correctly is what determines which alternatives are realistic. A single-segment annular failure adjacent to a prior fusion is a different clinical problem than global degenerative collapse, and the treatment path follows from that distinction.

A revision fusion extending the construct to the adjacent level increases mechanical stress on the next segment up, raises the probability of further adjacent segment disease, and restarts the surgical risk clock. Within ten years, revision rates after fusion can exceed 20%. In the illustrative scenario here, multilevel revision had already been discussed as the next step — a path the patient was not willing to accept.

The Valor team’s assessment pointed toward intra-annular fibrin injection at the adjacent symptomatic level. The fibrin procedure is designed to seal the painful annular defect, reduce inflammatory leakage from the nucleus pulposus, and create a stable biologic environment in which the outer annulus can remodel. Published outcome data supports this approach specifically in the FBSS patient phenotype: among failed back surgery patients tracked in outcome registries, 80% reported positive outcomes after fibrin disc treatment. Across the broader population, average VAS scores improved from 72.4 mm at baseline to 33.0 mm at 104 weeks. Individual outcomes vary, and these are population-level statistics, not personal guarantees.

The clinical discussion with this type of patient covers the realistic ceiling and floor of the procedure. Biologic disc repair is not a guarantee. Recovery is gradual rather than immediate. Adherence to the post-procedure protocol is a meaningful predictor of success. Equally important is what the fibrin procedure is not: it is not a substitute for epidural steroid injections — an approach that AAFP systematic review evidence has found not effective for chronic low back pain — and it is not a path back to heavy construction work. Setting that expectation honestly is part of the clinical conversation.

What Does the Procedure Involve for This Patient Profile?

The fibrin procedure in this setting is performed under imaging guidance. A thin catheter is advanced to the symptomatic annular defect. An FDA-approved fibrin sealant is delivered directly into the tear under fluoroscopic or CT guidance. The procedure takes under one hour and is performed with local anesthesia or light sedation. There are no incisions. The patient returns home the same day.

The fibrin sealant used in the procedure is FDA-approved as a sealant. Specific clinical applications, candidacy, and outcomes vary by patient.

In this illustrative case, the procedure targeted the L4-L5 posterior annular tear confirmed by discography. Post-procedure protocol included a structured return-to-activity plan, beginning with low-impact walking and progressing through functional rehabilitation milestones over weeks eight through twelve.

For patients evaluating this path, our guide on how to evaluate spine repair options after surgery walks through the decision framework in detail. The resource on evaluating regenerative spine care after failed surgery addresses the specific questions that come up most often in post-fusion consultations.

What Were the 24-Month Outcomes?

Across the 24-month follow-up window in this illustrative case, outcomes tracked against the published fibrin cohort data closely.

• VAS pain score: 72 mm at baseline → 33 mm at 104 weeks. This mirrors the published cohort mean of 72.4 mm to 33.0 mm at 104 weeks. Individual outcomes vary.
• Walking tolerance: Restored from four city blocks to sustained daily walking without forced stops from pain.
• Sleep: Night waking from positional pain resolved by week sixteen.
• Daily activities: Return to fishing, light woodworking, and lifting grandchildren — the functional targets the patient identified at intake.
• Revision fusion: Avoided through the 24-month mark.
• Satisfaction: Consistent with the 70% patient satisfaction rate documented at two-plus year follow-up in long-term fibrin outcome data. Individual outcomes vary.

These outcomes are not a guarantee for any individual patient. They represent one illustrative pattern drawn from the clinical data. A clinical evaluation is the only way to determine whether the fibrin procedure is an appropriate option for a specific person’s anatomy, history, and goals.

What Does This Case Illustrate for Patients Considering the Same Path?

Several clinical lessons emerge from this pattern that apply broadly to patients in similar circumstances.

Diagnosis before treatment. The annulogram — the imaging-guided diagnostic step that identifies every tear and leak in the discs — is what made the treatment decision precise. Without confirming that L4-L5 was the symptomatic source and that adjacent levels were negative, the treatment could have been misdirected. Patients who have been told they need revision fusion should ask whether the symptomatic level has been confirmed by provocation testing, not just MRI alone.

Adjacent segment disease is a known and trackable risk after fusion. It is not inevitable, but it is well-documented. Patients who have had a fusion and are now experiencing pain above or below the fused level should have that pattern evaluated specifically — not assumed to be the original problem recurring. Our resource on what adjacent segment disease is explains the mechanism in plain English.

Failed back surgery syndrome has more options than revision. The clinical default of offering revision fusion to FBSS patients is not the only path. For patients with a confirmed annular tear at a symptomatic level, biologic disc repair addresses the structural source of pain rather than extending a construct that is already placing mechanical stress on neighboring segments. See our guide on moving from failed back surgery toward lasting relief for a broader discussion of this pathway.

The procedure is not right for everyone. The clinical evaluation — including MRI review, symptom history, prior treatment response, and provocation testing — determines candidacy. Patients with neurological emergencies, spinal tumors, or pain unrelated to disc pathology are not candidates. A clinical evaluation is the only way to know for certain.

For patients who are early in their research, getting answers for post-surgery back pain and understanding what regenerative care after surgery involves are useful starting points before a consultation.

Frequently Asked Questions

Is intra-annular fibrin injection appropriate for patients who have already had spinal fusion?

For patients with confirmed annular tears at levels adjacent to a prior fusion, biologic disc repair is among the documented options. Published outcome data shows 80% of failed back surgery patients reported positive outcomes after fibrin disc treatment. Individual outcomes vary, and a clinical evaluation is the only way to determine whether a specific patient is a candidate.

How is the symptomatic disc level confirmed before treatment?

MRI identifies structural findings, but provocation discography — performed under imaging guidance — is the definitive diagnostic step that confirms which level is generating the patient’s concordant pain. Treatment is directed at confirmed symptomatic levels only.

What is the realistic timeline for recovery after the fibrin procedure?

Recovery is gradual rather than immediate. In outcome cohort data, VAS pain scores improved from 72.4 mm at baseline to 33.0 mm at 104 weeks — a two-year arc. Early functional improvements (sleep, reduced daily pain) often appear within the first few months. Full rehabilitation milestones extend over weeks eight through twelve post-procedure. Individual timelines vary.

Does the fibrin procedure cure failed back surgery syndrome?

The procedure is not a cure. It is designed to seal the annular tear that is driving discogenic pain, reduce inflammatory leakage, and create conditions for biologic remodeling. Whether that translates to meaningful pain reduction and functional improvement depends on individual anatomy, history, and adherence to the post-procedure protocol.

What if the fibrin procedure doesn’t work?

The fibrin procedure does not close off other options. For patients who do not achieve adequate relief, the clinical conversation continues. Revision surgical options remain available. A clinical evaluation before the procedure includes an honest discussion of what the realistic floor of outcomes looks like for a specific patient’s profile.

Where can I learn more about failed back surgery syndrome and my options?

Our detailed guide on what failed back surgery syndrome is covers causes, symptoms, and recovery options in plain English. The resource on evaluating non-surgical disc repair when surgery has failed walks through the decision framework step by step. For questions specific to your situation, a clinical consultation is the appropriate next step.

This content is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for evaluation by a qualified physician. Treatment decisions depend on your individual medical history and clinical findings. Schedule a consultation to discuss whether the procedure is right for you.

The fibrin sealant used in the procedure is FDA-approved as a sealant. Specific clinical applications, candidacy, and outcomes vary by patient.

The case described above is a composite illustrative scenario based on clinical patterns in failed back surgery syndrome patients. It does not represent any specific individual. No real patient information is included.